New book by Larry Connors Click here Improve your trading - See how
CLL is the most common form of leukemia in western countries. Recent therapeutic advances have improved the rate and duration of remission, although there is no consensus over the optimum regimen. CML has a lower incidence than CLL, but is a commercially lucrative indication for Gleevec (imatinib; Novartis) which continues to enjoy blockbuster success, having revolutionized the treatment of CML.
Scope
- Analysis of CLL and CML market based on a survey of 180 chronic leukemia specialists, supported by interviews carried out with key opinion leaders
- Segmentation of CLL and CML population by disease stage at presentation and proportion receiving anti-cancer therapy
- In-depth analysis of treatment patterns, regimens prescribed and treatment outcomes for CLL and CML by line of therapy and disease stage
- Ranking of key prescribing influences in CLL and CML, brand assessment of existing drug therapies, unmet needs and late-phase pipeline overview
Highlights of this title
Rituxan (rituximab; Biogen Idec/Genentech/Roche/Zenyaku Kogyo) has received considerable off-label use for chronic lymphocytic leukemia (CLL), particularly in the US. Positive Phase III data are likely to drive increased uptake in the EU. Conversely, several factors have restricted uptake of Campath (alemtuzumab; Takeda/Genzyme/Bayer Schering).
Gleevec is firmly established as the standard-of-care for newly diagnosed chronic phase CML, while the second generation tyrosine kinase inhibitors Sprycel (dasatinib; Bristol-Myers Squibb) and Tasigna (nilotinib; Novartis) are experiencing increasing uptake in Gleevec-resistant and accelerated phase patients.
Sprycel currently commands a higher market share than Tasigna for CML, benefiting from its first-to-market advantage. However, physicians perceptions of Sprycel and Tasigna show little differentiation, and there will be close competition for market share in the coming years.
Key reasons to purchase this title
- Understand prescribing trends and identify key factors that influence treatment choices in CLL and CML
- Examine unmet need within the CLL and CML markets and identify opportunities for new product development
- Enhance commercial positioning by increasing understanding of current dynamics within the CLL and CML markets
Key Topics Covered:
- CHAPTER 1 EXECUTIVE SUMMARY
- CHAPTER 2 INTRODUCTION AND SCOPE
- CHAPTER 3 COUNTRY TREATMENT TREES
- CHAPTER 4 CLL: DISEASE OVERVIEW, EPIDEMIOLOGY AND PATIENT SEGMENTATION
- CHAPTER 5 CLL: TREATMENT TRENDS AND TREATMENT OUTCOMES
- CHAPTER 6 CLL: PRESCRIBING INFLUENCES AND BRAND ASSESSMENT
- CHAPTER 7 CLL: UNMET NEEDS
- CHAPTER 8 CLL: LATE-PHASE PIPELINE OVERVIEW
- CHAPTER 9 CML: DISEASE OVERVIEW, EPIDEMIOLOGY AND PATIENT SEGMENTATION
- CHAPTER 10 CML: TREATMENT TRENDS AND TREATMENT OUTCOMES
- CHAPTER 11 CML: PRESCRIBING INFLUENCES AND BRAND ASSESSMENT
- CHAPTER 12 CML: UNMET NEEDS
- CHAPTER 13 CML: LATE-PHASE PIPELINE OVERVIEW
- BIBLIOGRAPHY
- APPENDIX A
- APPENDIX B
For more information visit http://www.researchandmarkets.com/research/9734be/stakeholder_insigh
Source: Datamonitor
CONTACT: Laura Wood, Senior Manager, Research and Markets Fax: +1 646 607 1907 (US) Fax: +353 1 481 1716 (Rest of World) e-mail: press@researchandmarkets.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
